Alexander H R, Grem J L, Pass H I, Hamilton M, McAtee N, Fraker D L, Allegra C J
Surgery Branch, National Cancer Institute, Bethesda, Maryland.
Oncology (Williston Park). 1993 May;7(5):37-42; discussion 42-4, 49-50, 53.
Gastric adenocarcinoma is typically diagnosed at an advanced stage, and even with "curative" gastrectomy, most patients die of recurrent disease. Neoadjuvant chemotherapy for locally advanced gastric cancer is an experimental treatment strategy that may increase resectability and improve survival for patients afflicted with an almost uniformly fatal neoplasm. At our institution, we are evaluating the efficacy of fluorouracil, leucovorin, and interferon alfa-2A administered for three cycles, followed by surgery and consolidation therapy for patients with T3-4, N1-2, M0 gastric adenocarcinoma. The rationale for the use of neoadjuvant therapy combined with radical extirpative surgery in this setting and related issues are discussed.
胃腺癌通常在晚期被诊断出来,即使进行了“根治性”胃切除术,大多数患者仍死于疾病复发。局部晚期胃癌的新辅助化疗是一种实验性治疗策略,可能会提高可切除性,并改善患有几乎一致致命肿瘤患者的生存率。在我们机构,我们正在评估对T3 - 4、N1 - 2、M0期胃腺癌患者给予氟尿嘧啶、亚叶酸钙和干扰素α - 2A三个周期治疗,随后进行手术及巩固治疗的疗效。本文讨论了在这种情况下使用新辅助治疗联合根治性切除手术的基本原理及相关问题。